# telehealthglow.com # Telehealth GLOW — The GLOW research-peptide blend (GHK-Cu + BPC-157 + TB-500), decomposed > Independent editorial summary of the GLOW research-peptide blend. Three components — GHK-Cu, BPC-157, TB-500 — three repair pathways, zero peer-reviewed combination trials. Three peptides. Three pathways. One unstudied stack. A plain-English reading of what the GHK-Cu, BPC-157, and TB-500 literature actually says — and what it carefully does not. ## The plain signal GLOW is not a drug. It is three separate research peptides — GHK-Cu, BPC-157, and TB-500 — co-packaged in a single vial by convention, not by any approved clinical protocol. GHK-Cu (the copper-tripeptide, Channel R on this site) is studied for skin matrix proteins — collagen, elastin, the structural scaffolding that keeps skin firm. BPC-157 (Channel G) is studied for tendon healing and new blood-vessel formation. TB-500 (Channel B) is a fragment of a natural protein that helps cells migrate and wounds close. Put the three together and the mechanistic rationale for the blend becomes visible: a matrix signal, a vascular signal, and a cell-mobility signal firing in parallel. What that rationale is not is evidence. No peer-reviewed study has ever tested the three-peptide GLOW blend in a controlled trial. What people report from research communities — brighter skin, faster wound closure, easier recovery from a nagging injury — is covered honestly on [the effects page](/effects), labeled clearly as anecdotal, not clinical evidence. This site exists to make the gap between the mechanistic thesis and the missing evidence visible. ## What GLOW actually is The first thing to know about the GLOW blend is that it is not one molecule. It is three. Commercial research-chemical vials sold under the GLOW label are co-formulations of three separate peptides: glycyl-L-histidyl-L-lysine bound to copper (GHK-Cu), the fifteen-amino-acid pentadecapeptide BPC-157, and a seventeen-amino-acid synthetic fragment of thymosin beta-4 marketed as TB-500. Typical advertised mass is 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 per vial [16]. There is no covalent bond between the components. The 'blend' is exactly that — three peptides reconstituted in the same diluent. The GLOW nickname is community-derived. It traveled outward from peptide forums and lay newsletters into a stable label for the three-component stack, and from there into vendor catalogs. No peer-reviewed paper uses the word. The branding is downstream of marketing, not biology [16]. Each component has its own decades-long research record. GHK-Cu was first isolated from human plasma in the 1970s and has the deepest cosmetic and matrix-remodeling literature of the three [2]. BPC-157 has a sprawling rodent dataset for tendon, vascular, and gut healing, plus three small human pilot studies [9]. TB-500 inherits the broader thymosin beta-4 evidence base, which includes a published Phase III ophthalmic trial [12]. What does not exist — anywhere in the indexed literature — is a single peer-reviewed study of the three together [16]. ## Three components, three channels The clearest way to think about GLOW is as three independent repair signals firing in parallel. **Channel R — GHK-Cu** is a copper-carrying tripeptide that modulates extracellular-matrix gene expression. In transcriptomic work using the Broad Institute Connectivity Map, GHK-Cu at 1-10 nM altered expression of roughly thirty-one percent of the human genome after twenty-four hours, with about fifty-nine percent of affected genes upregulated [2]. The downstream effect on the matrix is what you would expect from a signal that re-tunes collagen, elastin, and proteoglycan programs at once. **Channel G — BPC-157** is the angiogenic and cytoprotective member. The most-replicated rodent effect is upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), with downstream Akt phosphorylation and endothelial nitric oxide synthase activation [8]. In a transected Achilles tendon model, intraperitoneal BPC-157 at 10 µg/kg accelerated tendon outgrowth and fibroblast migration [7]. Three small human pilots — knee pain (n=14), interstitial cystitis (n=12), intravenous safety (n=2) — round out the human dataset [9]. **Channel B — TB-500** is a synthetic fragment of thymosin beta-4 spanning residues 1-17, the actin-binding domain. Full-length thymosin beta-4 binds monomeric G-actin one-to-one with nanomolar affinity, maintaining a free pool of unpolymerized actin that cells draw on to remodel their cytoskeleton during migration [11]. The fragment inherits the binding behavior; the parent molecule's clinical record (corneal Phase III, post-myocardial-infarction work in mice) supplies most of the supporting context [12, 13]. The synergy claim that justifies stacking these three is mechanistic: matrix remodeling, capillary supply, and cell migration are three sequential requirements of wound repair, so a co-formulation that pushes all three at once might compress the timeline. That is a plausible hypothesis. It is not data. ## What the GLOW combination has not been studied Search the indexed literature for a clinical or preclinical study of the full GHK-Cu + BPC-157 + TB-500 combination and the result is empty [16]. No randomized trial. No controlled animal experiment. No published case series of the three-component stack. The per-component evidence does not transfer to the combination by inference, because dose-response, interaction, and timing all change when peptides are co-administered. The two-component subset (BPC-157 + TB-500, often nicknamed 'Wolverine') is the most-cited stack in the lay literature, but it too lacks a controlled combination trial — what exists is a parallel set of single-component studies that practitioners pattern-match into a stack [16]. This is the editorial gap the design of this site tries to make visible. Each component card on this page carries a single-channel border — red, green, or blue. The three only superimpose at the very center of the composite plate above, and even there they almost-but-do-not-quite register. The visual vocabulary mirrors the evidence: three signals that have been studied separately, presented together by convention, with no published trial of the merged signal. ## Regulatory posture — why telehealth GLOW is constrained GLOW intersects three separate regulatory frames, and all three constrain the most-searched intent that brings readers to a page like this one: 'can I get GLOW via telehealth?' First, the U.S. Food and Drug Administration added BPC-157 to its Category 2 bulk drug substances list in September 2023, citing concerns about immune reactions, manufacturing impurities, and the absence of human safety data. Category 2 status blocks 503A traditional compounding pharmacies and 503B outsourcing facilities from preparing the substance for human use [16]. TB-500 and injectable GHK-Cu are similarly restricted when intended for injection. Second, the World Anti-Doping Agency classifies BPC-157 under S0 — Non-Approved Substances, prohibited at all times, no therapeutic-use exemption — and thymosin beta-4 (and by extension TB-500) under S2 — Peptide Hormones, Growth Factors and Related Substances, also prohibited at all times [16]. Tested athletes should treat the entire blend as banned. Third, the FDA has not approved the full GLOW combination, any of its components, or anything resembling it for any human therapeutic indication. There is no labeled dose, no labeled route, no labeled population. Telehealth prescribing of GLOW or its components for human use is therefore not consistent with the post-September-2023 regulatory landscape. This site is an independent editorial publisher and does not provide telehealth services, prescriptions, referrals, or product sales. The 'telehealth' in the domain name is editorial framing — a position the publisher occupies relative to a fast-moving prescribing landscape, not a service the site offers. If you came here looking for a virtual clinic, you are in the wrong place. If you came here looking for what the research actually says about the three components and the still-empty space where the combination evidence would go, the rest of the site is for you. --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription. --- # GLOW reported effects, benefits, and safety — three components, three cautions > GLOW blend effects reported by the research-use community: skin brightness, tissue repair, wound healing, injection-site reactions. Safety cautions on angiogenesis, copper, WADA status, and unstudied combined pharmacokinetics. Anecdotal, not clinical evidence. Community accounts of the GHK-Cu + BPC-157 + TB-500 stack, labeled plainly as anecdotal, not clinical evidence, alongside cited safety cautions for each constituent. No doses. No recommendations. ## The plain version GLOW is a research blend of three peptides — GHK-Cu (a copper-carrying tripeptide), BPC-157 (a gut-derived repair peptide), and TB-500 (a cell-migration fragment of thymosin beta-4) — that has never been tested in a controlled clinical trial. Every claim about what the blend does is extrapolated from single-component research, most of it in animals. What people report from research-use communities is a separate category of information: not clinical evidence, but not nothing either. This page sets out both layers honestly. The first is what community accounts describe, labeled anecdotal throughout. The second is what each peptide's mechanism and regulatory status mean for specific groups — and those cautions are grounded in cited literature, not forum consensus. ## What people report **Anecdotal, not clinical evidence.** The accounts below come from research-use community write-ups and clinic blog summaries of the GHK-Cu + BPC-157 + TB-500 stack. No verified dose is stated here because no verified dose exists for the GLOW blend. The blend has never been studied in a controlled trial; no adverse-event monitoring has been conducted on any of these reports. Frequency labels reflect how often each effect appears across those community accounts. **An overall skin 'glow' — brighter, more even-looking complexion.** Frequently reported. Community accounts consistently describe skin appearing brighter and more radiant after a few weeks, attributed mainly to the GHK-Cu copper-tripeptide arm's documented collagen and matrix-remodeling activity [1,2]. This is cosmetic community language, not a clinical endpoint. **Smoother skin texture and improved tone.** Frequently reported. Skin that feels smoother and looks more hydrated or 'plump' over roughly three to six weeks is a recurring description, credited to the GHK-Cu component's matrix-remodeling record [1]. **Softer-looking fine lines and wrinkles.** Commonly reported. Accounts running eight to twelve weeks sometimes note fine lines looking slightly softened, which users attribute to GHK-Cu's collagen-stimulating research record. Results are described as varying considerably with age and baseline skin condition. **Faster healing of wounds and better-looking scars.** Commonly reported. Wounds, post-procedure redness, and older scars appearing to fade or close faster is a recurring theme attributed to the BPC-157 tissue-repair and TB-500 cell-migration-and-anti-scarring arms working alongside GHK-Cu [7,11]. These are personal accounts over weeks to months, not measured clinical results. **Faster recovery from a nagging tendon, joint, or soft-tissue injury.** Frequently reported. Carried from the BPC-157 + TB-500 recovery-stack literature the blend builds on, people describe a stubborn shoulder, knee, or Achilles issue easing over roughly three to four weeks. No controlled GLOW study exists. **Reduced hair thinning or improved hair density.** Occasionally reported. Less hair shedding or improved density is sometimes noted as a secondary effect, attributed to GHK-Cu's documented hair-follicle activity [5]. **Lower joint or muscle achiness alongside the skin effects.** Occasionally reported. A subset of accounts mention reduced aches or joint discomfort appearing before any visible skin change, credited mainly to the BPC-157 and TB-500 arms. --- **Adverse effects from the same community accounts:** **Injection-site sting or burn during the shot.** Frequently reported. The most consistent downside: a 30–60 second sting as the GHK-Cu copper-tripeptide complex goes in, usually fading within a minute. Community accounts suggest diluting more, warming the vial, and injecting slowly. **Injection-site redness, itching, or irritation after the shot.** Commonly reported. Local redness or itching lasting under a day, more often when injection sites are not rotated; attributed to both the copper-tripeptide and the subcutaneous route shared by all three peptides. **Fatigue or a mild headache, mostly in the first week or two.** Commonly reported. Early-on tiredness or low energy, sometimes with a dull head-pressure feeling, described as usually settling as the body adjusts. **Facial flushing, warmth, or a brief metallic taste.** Occasionally reported. Warmth or visible flushing within 5–15 minutes, or a short-lived metallic taste, attributed to the copper in the GHK-Cu arm. **Mild bloating, nausea, or increased appetite.** Occasionally reported. Transient bloating (more often attributed to the TB-500 arm), occasional mild nausea or dizziness, and increased appetite in the early period; generally described as resolving without intervention. ## Safety and cautions The following cautions are grounded in the mechanism or regulatory record of each constituent — not in observed harms from the GLOW blend itself, which has no formal safety study. **Athletes subject to anti-doping testing: the blend is off-limits.** TB-500 is the synthetic actin-binding fragment of thymosin beta-4, and thymosin beta-4 sits on the WADA Prohibited List (class S2: peptide hormones, growth factors, and mimetics), banned at all times in and out of competition. Using GLOW implicates anti-doping rules regardless of intent or the skin-focused marketing context. A 2026 Sports Medicine review that explicitly names TB-500 and GHK-Cu among unapproved research peptides operating largely outside regulatory oversight reinforces that boundary [19]. **People with an active or recent cancer: a specific mechanistic concern.** BPC-157 promotes new blood-vessel growth via VEGFR2 up-regulation and the VEGFR2–Akt–eNOS signaling pathway [8]. TB-500's parent protein thymosin beta-4 likewise promotes angiogenesis and cell migration [11]. Because solid tumors depend on new blood-vessel formation for their blood supply, accelerating that process is a theoretical concern raised in the peptide literature. No human study has tested this risk for any component or for the GLOW blend; the caution is mechanistic, not a demonstrated clinical harm [9]. **People with Wilson's disease or any copper-overload condition: GHK-Cu deliberately delivers copper into tissue.** The GHK-Cu arm is a copper(II)-tripeptide complex. Skin-penetration work shows it forms a measurable dermal copper depot — in one ex-vivo study, 97 micrograms per cm² was retained in the dermis over 48 hours [19]. In anyone who cannot clear copper normally, adding a copper-carrying peptide carries a mechanistic concern around copper accumulation. This is grounded in the biochemistry of the GHK-Cu component, not in a study of harm from the GLOW blend [2]. **Treat the blend itself as untested: mismatched half-lives, no combined safety data.** GLOW is a supplier- and clinic-formulated combination with no controlled trials. Its three constituents clear at very different rates — the small GHK tripeptide and short-lived BPC-157 (elimination half-life under 30 minutes in animals) versus the thymosin beta-4 fragment — and a co-formulated injection mixes molecules with mismatched pharmacokinetics that have never been characterized together. A 2026 Sports Medicine review naming all three constituent types concludes that rigorous human safety data are scarce and there is potential for serious harm [19]. **GLOW is not FDA-approved; its most human-data-poor component should be treated as investigational.** A 2025 narrative review of BPC-157 found only three small human pilot studies and concluded it should be considered investigational and used with caution until well-designed trials exist [9]. Because the blend can be no better evidenced than its weakest-studied constituent, GLOW inherits that investigational framing. --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription. --- # GLOW blend research — GHK-Cu, BPC-157, TB-500 evidence per channel > Channel-by-channel summary of the GLOW research-peptide blend literature. GHK-Cu matrix and wound-healing evidence, BPC-157 angiogenesis and tendon data, TB-500 / thymosin beta-4 migration and ophthalmic trials, plus the unstudied combination. What has been published on each GLOW component — and the missing peer-reviewed study of the three together. ## What to expect from this page This page works through three separate research literatures — one per GLOW component — rather than treating the blend as a single thing that has been studied, because it has not been. GHK-Cu has the deepest research record of the three, anchored in cosmetic dermatology and wound-healing biology, with one controlled diabetic-ulcer trial from 1994 and a large body of cell-culture and transcriptomic work since. BPC-157 has an extensive rodent dataset and three small human pilots, the most recent of which was a 2-subject intravenous safety report from 2025. TB-500 inherits almost all of its evidence base from the full-length parent protein (thymosin beta-4), not from the commercial seventeen-residue fragment itself. Reading these three channels in sequence gives you the honest picture of what GLOW actually means in the indexed literature: three independently studied signals, zero studies of the three together. ## How this page is organized The GLOW blend is three molecules. The research literature is three datasets. This page works through them in order — channel R (GHK-Cu), channel G (BPC-157), channel B (TB-500) — then ends at the place the literature ends, which is the absence of any combination trial. Every quantitative claim cites a specific paper in the references index. The taxonomy is structural, not editorial. We do not weigh evidence across channels (you cannot meaningfully compare a 1994 diabetic-ulcer wound-closure rate to a 2025 narrative-review pilot count), and we do not rank the components against one another. We summarize what each has been studied for, in what model, at what dose, with what result. ## Channel R — GHK-Cu (extracellular matrix and wound healing) GHK-Cu is the deepest-studied of the three components, primarily in cosmetic dermatology and wound-healing contexts. The molecule is a glycyl-L-histidyl-L-lysine tripeptide chelated to a single copper(II) ion, with a molecular weight of about 340.8 daltons. Its native concentration in human plasma declines with age, a quiet biographical detail that has anchored most of the regenerative interest [2]. The most-cited human evidence is a 1994 Mulder study of topical GHK-Cu (formulated as a 'lamin' gel) applied twice daily to diabetic neuropathic foot ulcers. Wound closure ran roughly three times faster than placebo (P<0.01), and the treatment group had a lower infection rate [1]. The trial is now thirty years old, but it remains the most-cited controlled human result for the tripeptide. The mechanistic interest accelerated in 2014 with Pickart's Connectivity Map analysis. At 1-10 nM in cell culture, GHK-Cu shifted expression of about thirty-one percent of measured human genes (defined as a fifty-percent or greater change at twenty-four hours), with fifty-nine percent of those genes upregulated [2]. The affected programs cluster around matrix synthesis (collagen, elastin, decorin, dermatan and chondroitin sulfate), antioxidant defense, and DNA repair. The framing in the paper — 'resetting the human genome to health' — is rhetorical; the underlying transcriptomic signal is real but its therapeutic translation remains a research question, not a settled finding. In vivo, intraperitoneal GHK-Cu has been studied in mouse models of acute lung injury and bleomycin-induced pulmonary fibrosis. The peptide reduced TNF-alpha and IL-6 output, attenuated lung-injury histology [3], and reversed MMP-9 / TIMP-1 imbalance via NF-kB and TGF-beta1 pathways in the fibrosis model [4]. The pattern across the in vitro and animal work is consistent: GHK-Cu rebalances inflammatory and matrix-turnover programs rather than dramatically pushing any single pathway. In hair-follicle research, a tripeptide-copper complex stimulated dermal papilla cell proliferation, raised VEGF, lowered TGF-beta1, and promoted elongation of human hair follicles ex vivo at picomolar-to-nanomolar concentrations [5]. The recent formulation literature — including 2025 work on liposomal encapsulation — addresses the longstanding bioavailability constraint that has limited topical delivery of free GHK-Cu [17]. What the GHK-Cu literature does not yet contain is a large modern randomized trial in any indication. The 1994 wound study has not been replicated at scale. Cosmetic-dermatology evidence is broader but methodologically uneven, and the bulk of mechanistic insight remains in vitro. ## Channel G — BPC-157 (angiogenesis, tendon, gut-brain axis) BPC-157 — Body Protection Compound 157, also called PL-14736 in its earlier clinical-development incarnation — is a fifteen-amino-acid pentadecapeptide derived from a protective protein in human gastric juice. Sequence GEPPPGKPADDAGLV. The peptide is notably stable in human gastric juice (which is, after all, its native environment), and that stability has underwritten the persistent interest in oral and gastrointestinal delivery. The most-replicated mechanism is angiogenesis through the VEGFR2-Akt-eNOS pathway. BPC-157 upregulates expression and endocytosis of vascular endothelial growth factor receptor 2 on endothelial cells; downstream phosphorylation of Akt activates endothelial nitric oxide synthase, increasing nitric oxide release and driving capillary sprouting into healing tissue [8]. A related 2020 paper traced the same vascular biology to a Src-Caveolin-1-eNOS pathway in rat ischemia models, where 10 µg/kg intraperitoneal BPC-157 restored vasomotor function [8]. In tendon biology, intraperitoneal BPC-157 at 10 µg/kg accelerated tendon outgrowth, cell survival, and cell migration in a transected Achilles tendon model in rats [7]. A parallel in vitro study found that BPC-157 dose- and time-dependently upregulated growth hormone receptor expression in tendon fibroblasts at both mRNA and protein levels, potentiating GH-driven proliferation [6]. The tendon evidence base is the strongest signal in the BPC-157 dataset, but it remains rodent-only with the exception of small pilot work. The Sikiric group has spent the last decade building a unifying framework in which BPC-157 acts as a cytoprotection mediator with neurotransmitter-like activity, simultaneously modulating dopaminergic, serotonergic, glutamatergic, GABAergic, and nitric-oxide systems via the brain-gut axis [10]. A 2025 follow-up reframed the angiogenic mechanism as selective modulation — sparing protective NO functions while blunting cytotoxic ones — in response to a 2025 narrative review that raised safety questions [18]. That 2025 narrative review by McGuire and colleagues is the current state-of-the-art human-evidence synthesis. Through March 2025, the authors found robust preclinical evidence for accelerated tendon, ligament, muscle, and bone healing, but only three pilot human studies in the indexed literature: knee pain (n=14, 87.5% relief), interstitial cystitis (n=12, 80-100% symptom resolution), and an intravenous safety report (n=2) [9]. The authors emphasize that BPC-157 must continue to be considered investigational. The most-cited gap in the BPC-157 human evidence is the unpublished Phase II Pliva trial. The compound, then under the development name PL-14736, advanced into a Phase II multicenter, randomized, double-blind, placebo-controlled enema trial for mild-to-moderate ulcerative colitis. The trial completed; full results were never published in a peer-reviewed journal [16]. The gap is sometimes described in lay sources as a 'terminated' trial; the more accurate framing is 'completed without peer-reviewed publication.' ## Channel B — TB-500 (thymosin beta-4 fragment, migration and ophthalmology) TB-500 is a seventeen-amino-acid synthetic peptide corresponding to residues 1-17 of full-length thymosin beta-4 (Tβ4), a forty-three-amino-acid peptide that sequesters monomeric G-actin and maintains the free actin pool that cells draw on for cytoskeletal remodeling [11]. The fragment inherits the actin-binding domain; the broader thymosin beta-4 clinical record carries most of the supporting context. The canonical biochemistry: full-length Tβ4 binds G-actin one-to-one with nanomolar affinity, maintaining a cytoplasmic pool of unpolymerized actin available for rapid F-actin assembly during migration [11]. This is the mechanism that underwrites the migration-promoting effects across multiple cell types — keratinocytes, fibroblasts, endothelial cells, myoblasts. In 2004, Bock-Marquette and colleagues reported in Nature that intraperitoneal Tβ4 after coronary ligation in mice activated integrin-linked kinase and Akt, promoted cardiac cell migration and survival, and improved left-ventricular function — the first molecule, they argued, to initiate simultaneous myocardial and vascular regeneration after systemic administration [13]. In a 2010 rat embolic stroke model, Tβ4 at 6 mg/kg intraperitoneal starting twenty-four hours post-stroke (every three days, four doses) improved neurological score, increased oligodendrocyte progenitor cells, and increased axonal density [14]. In a 2011 mouse muscle-injury study, endogenously released Tβ4 acted as a chemoattractant for myoblasts, drawing them into damaged muscle tissue [15]. The strongest human data sits in ophthalmology. A 2023 randomized, placebo-controlled, double-masked Phase III trial of 0.1% RGN-259 (thymosin beta-4) ophthalmic solution in neurotrophic keratopathy reported increased complete corneal healing versus placebo and improved patient-reported comfort over twenty-eight days of multi-daily dosing [12]. A 2024 engineered tandem-Tβ4 construct improved manufacturability and accelerated corneal re-epithelialization in animal models versus monomeric Tβ4 [unpublished extension reported in PMC] — a sign that the parent molecule's translational program remains active. What the TB-500 fragment specifically does not yet have is a published clinical trial in any indication. The clinical record belongs to full-length thymosin beta-4. Extrapolation from the parent peptide to the seventeen-residue fragment is reasonable mechanistically (the actin-binding domain is conserved) but is not the same as evidence. ## The unstudied combination And then there is the white space. No peer-reviewed clinical or preclinical study has tested the full GHK-Cu + BPC-157 + TB-500 combination as a single intervention [16]. The synergy rationale is mechanistic: matrix remodeling, capillary supply, and cell migration are three sequential requirements of wound repair, so co-administration might compress the timeline. Each component's individual record supports the per-channel claim. The cross-channel interaction does not appear in the indexed literature. This matters more than it might sound. Combination pharmacology is not a sum of monotherapies. Dose-response curves shift. Pharmacokinetic interactions emerge. Mechanistic effects can amplify or cancel. None of those questions have been studied for GLOW. The community-derived 'GLOW' label travels through vendor catalogs and forum posts without ever passing through a randomized trial. The two-component BPC-157 + TB-500 subset — sometimes nicknamed 'Wolverine' — is the most-cited stack in the lay literature, but it too lacks a controlled combination trial. What exists is a parallel set of single-component studies that practitioners pattern-match into a stack [16]. The honest summary: three components, three independent evidence bases, zero peer-reviewed combination studies. The site reflects this structure in its visual vocabulary — three channels that almost-but-do-not-quite register — because that asymmetry between component evidence and combination evidence is the most important thing a reader can leave this page knowing. --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription. --- # GLOW research-context dosing — what published studies actually used > Research-context dosing for the three GLOW components. Doses, routes, and durations from published GHK-Cu, BPC-157, and TB-500 studies. The GLOW combination has no validated human or animal dosing. Per-channel summary of the doses, routes, and durations actually used in published GHK-Cu, BPC-157, and TB-500 research. The blend itself has no validated dosing. ## Before any numbers This page lists doses, routes, and durations from published research — not guidance for any individual. It answers the question 'what was studied?' not 'what should someone take?' Those are different questions, and for the GLOW blend specifically the second one cannot be answered from the literature because the combination has never been dosed in a controlled human trial. The commercial vial ratio (50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500) is a supplier convention, not a literature-derived figure. What follows is a channel-by-channel account of the doses, species, routes, and durations that actually appear in the published studies cited elsewhere on this site — nothing more, nothing less. ## A framing note before any numbers GLOW is a research-peptide blend. None of its components are FDA-approved for any human therapeutic indication, and the combination has never been studied in humans or animals [16]. This page is not a dosing guide. It is a literature summary — a list of the doses, routes, and durations that were actually administered in the published studies cited elsewhere on this site. That distinction is the entire point. Research-context dose reporting answers the question 'what was studied?' It does not answer 'what should a person take?', because no published research supports that latter question for any of the three components in a human self-administration setting. The numbers below are reported in third person, attributed to specific studies, and bounded by the model the dose was used in (rodent, ex vivo, human pilot, in vitro). ## Channel R — GHK-Cu research doses GHK-Cu research uses three principal dose registers depending on the model. **Topical cosmetic and dermatology studies** have generally used GHK-Cu formulations at 0.05% to 0.2% in cream or serum vehicles applied once or twice daily. The 1994 Mulder diabetic-ulcer trial used a 'lamin' GHK-Cu gel applied twice daily for the trial duration [1]. The 2025 liposomal formulation literature is exploring whether encapsulation can meaningfully raise transdermal flux at lower concentrations [17]. **Transcriptomic and cell-biology work** has used GHK-Cu in cell culture at 1-10 nanomolar — the concentration range that produced Pickart's roughly thirty-one percent genome-wide expression shift in the Connectivity Map analysis [2]. Hair-follicle ex vivo work has used a related AHK-Cu analog at picomolar-to-nanomolar concentrations [5]. **In vivo rodent fibrosis and lung-injury studies** have used GHK-Cu at approximately 3 mg/kg intraperitoneal in multi-day dosing schedules [3, 4]. These doses are at the higher end of the GHK-Cu literature and reflect the in vivo demands of an inflammatory or fibrotic challenge model rather than a cosmetic context. Half-life is short — GHK-Cu has a plasma half-life on the order of minutes — but copper-binding affinity prolongs tissue residence. Stability is the formulation-critical variable: oxidation can dissociate the copper-tripeptide chelate, so reconstitution and storage protocols matter. ## Channel G — BPC-157 research doses The most-cited rodent dose across the BPC-157 literature is 10 µg/kg intraperitoneal. This is the dose used in the Achilles tendon transection model [7], the Src-Caveolin-1-eNOS vasomotor work [8], and most of the gut-protection and brain-gut axis studies summarized by the Sikiric group [10]. Oral 10 µg/kg administered via drinking water has also been used in many studies, leveraging BPC-157's notable stability in gastric juice. **Pilot human studies** have used different regimens. The McGuire 2025 narrative review notes that the published human pilots used local injection (intra-articular for the knee-pain cohort), intravesical instillation (for interstitial cystitis), or intravenous administration (for the two-patient safety report) [9]. Reported local doses ran in the 200-500 µg range, but the dataset is small enough that any 'typical' figure is more anecdote than guideline. **The unpublished Pliva Phase II** of BPC-157 (then PL-14736) for ulcerative colitis used a rectal enema with dose escalation [16]. Specific dose levels have not been published in a peer-reviewed venue. Plasma half-life is short — approximately thirty minutes intraperitoneal in rats — but biological effects persist far longer, suggesting downstream signaling cascade activation rather than direct receptor occupancy [9]. ## Channel B — TB-500 research doses TB-500 — the seventeen-residue fragment of thymosin beta-4 — does not have its own dedicated dose-finding literature. Most of what informs the research-context dose register comes from full-length thymosin beta-4 studies. **Rodent stroke and cardiac models** have used full-length Tβ4 at 6 mg/kg intraperitoneal. The 2010 Morris embolic stroke study used 6 mg/kg IP starting twenty-four hours post-stroke, dosed every three days for four total doses [14]. The 2004 Bock-Marquette cardiac work used intraperitoneal Tβ4 after coronary ligation; specific mg/kg figures vary across the follow-up literature [13]. **Ophthalmic trials** of RGN-259 (Tβ4) have used a 0.1% topical solution applied multiple times daily for twenty-eight days in the Phase III neurotrophic-keratopathy trial [12]. Engineered tandem-Tβ4 corneal work has used topical ophthalmic application in animal models. **Phase I intravenous trials** of full-length Tβ4 in human subjects have explored single doses from 42 mg to 1260 mg, with no major safety signal reported at the cited dose levels [from the broader thymosin beta-4 development program, summarized in 11, 12]. Full-length Tβ4 has a plasma half-life of approximately two hours in human trials. The seventeen-residue fragment's pharmacokinetics are not as well characterized in the published literature. ## The GLOW combination has no validated dosing Commercial GLOW vials advertised in research-chemical catalogs typically contain 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 per vial. This ratio is vendor convention, not literature-derived [16]. No peer-reviewed paper has studied the combination at this or any other ratio. The gap between component-level evidence and combination dosing is more than a documentation issue. Combination pharmacology can produce dose-response shifts, pharmacokinetic interactions, and emergent toxicities that single-component data does not predict. The absence of GLOW combination studies means there is no published basis for any specific dose, route, schedule, or duration of the three together. The routes of administration that appear in the per-component literature — intraperitoneal in rodents, topical for GHK-Cu cosmetic work and Tβ4 ophthalmic trials, intra-articular and intravesical in BPC-157 human pilots, oral gavage in BPC-157 rodent gut studies, intravenous in full-length Tβ4 Phase I — are all single-component routes [16]. None of them was developed or validated for the three-peptide blend. --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription. --- # GLOW blend FAQ — common questions about GHK-Cu + BPC-157 + TB-500 > Answers to common questions about the GLOW research-peptide blend: ingredients, mechanism, telehealth status, FDA Category 2 posture, WADA classification, combination evidence, and per-component risks. What readers most often ask about the GLOW research-peptide blend, with answers grounded in the published literature and the current regulatory posture. ## What is the GLOW peptide blend and what is actually in it? GLOW is a research-peptide co-formulation of three separate peptides reconstituted in a single vial: GHK-Cu (a copper-binding tripeptide), BPC-157 (a fifteen-amino-acid pentadecapeptide derived from a protein in human gastric juice), and TB-500 (a seventeen-amino-acid synthetic fragment of thymosin beta-4) [16]. Typical advertised vial content is 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500, though this ratio is a vendor convention rather than something derived from any published study. The 'GLOW' name itself is community-derived and does not appear in the peer-reviewed literature [16]. ## How do GHK-Cu, BPC-157, and TB-500 work together in the GLOW blend? Each component targets a different repair pathway. GHK-Cu modulates extracellular-matrix gene expression — collagen, elastin, proteoglycans, MMP/TIMP balance — and damps inflammatory cytokine output [2]. BPC-157 drives angiogenesis through the VEGFR2-Akt-eNOS pathway and supports cytoprotection across vascular, tendon, and gut tissue in rodent models [7, 8]. TB-500 sequesters monomeric G-actin, enabling rapid cytoskeletal remodeling and cell migration [11]. The synergy rationale stacks all three because matrix, vasculature, and migration are three sequential needs of wound repair. The synergy is mechanistic hypothesis, not evidence — the combination itself has not been studied [16]. ## Can I get the GLOW blend via telehealth? This question is what 'telehealthglow.com' is named for, and the honest answer is that the regulatory frame around GLOW makes the question more complicated than it might appear. As of September 2023, BPC-157 sits on the FDA's Category 2 bulk drug substances list, which blocks 503A and 503B compounding pharmacies from preparing it for human use. Injectable GHK-Cu and TB-500 face related restrictions. Telehealth prescribing of GLOW or its components for human use is not consistent with this regulatory posture [16]. This site does not provide telehealth services, prescriptions, referrals, or product sales — we are an independent editorial publisher summarizing the research literature. ## Is the GLOW blend prescribed via telehealth in the United States? The telehealth peptide-prescribing landscape grew rapidly from 2020 through 2023 and contracted sharply after the September 2023 FDA Category 2 listing of BPC-157. Compounding restrictions, state medical board attention, and payment-processor risk policies have together narrowed the channels through which GLOW or its components were previously offered for human use [16]. We do not publish a list of providers and do not have a position on individual prescribing practices — those are between a clinician, a patient, and the relevant regulators. We do publish what the FDA's posture is, what WADA's posture is, and what the published literature does and does not say. ## Why is BPC-157 restricted by the FDA — and does that affect the GLOW blend? The FDA's September 2023 decision to add BPC-157 to its Category 2 bulk drug substances list cited concerns about potential immune reactions, manufacturing impurities, and the absence of human safety data [16]. Category 2 status blocks both 503A traditional patient-specific compounding and 503B outsourcing-facility batch compounding from preparing the substance. Because BPC-157 is one of the three components of GLOW, the GLOW blend itself is constrained by the same restriction — a compounding pharmacy cannot legally prepare a co-formulation that includes a Category 2 substance. The TB-500 and injectable GHK-Cu components face related restrictions when intended for injection. ## Has the GLOW blend itself been studied in a clinical trial? No. A search of the indexed literature for any peer-reviewed clinical or preclinical study of the full GHK-Cu + BPC-157 + TB-500 combination returns nothing [16]. Per-component evidence exists — particularly for GHK-Cu in wound healing [1] and for full-length thymosin beta-4 in ophthalmology [12] — but the three-component combination has not been studied. The two-component BPC-157 + TB-500 subset (the 'Wolverine' stack) also lacks a controlled combination trial. Synergy claims for GLOW are mechanistic extrapolation, not data. ## What does the research say about each GLOW component? GHK-Cu has the longest research record. Its 1994 diabetic-ulcer trial reported wound closure roughly three times faster than placebo [1], and Pickart's 2014 transcriptomic work showed it modulates expression of about thirty-one percent of the human genome at 1-10 nM [2]. BPC-157 has a deep rodent dataset for tendon, vascular, and gut healing [6, 7, 8, 10], plus three small human pilots (knee pain n=14, interstitial cystitis n=12, IV safety n=2) summarized in a 2025 narrative review [9]. TB-500 inherits the thymosin beta-4 evidence base, which includes a published Phase III ophthalmic trial in neurotrophic keratopathy [12] and rodent cardiac and stroke work [13, 14]. The /research page works through each component channel in detail. ## Is GLOW banned for athletes under WADA rules? Yes — for two of the three components, and effectively for the blend as a whole. The World Anti-Doping Agency classifies BPC-157 under category S0 (Non-Approved Substances), prohibited at all times, with no therapeutic-use exemption pathway [16]. Thymosin beta-4 (and by extension TB-500) is classified under S2 (Peptide Hormones, Growth Factors and Related Substances), also prohibited at all times. GHK-Cu is not specifically named in the WADA prohibited list, but copper-binding peptides intended to alter tissue remodeling fall under the agency's general framework for unapproved performance-influencing substances. Tested athletes should treat the entire blend as banned. ## What are the typical research doses used in published studies of each component? The most-cited rodent BPC-157 dose is 10 µg/kg intraperitoneal [7, 8, 10]. GHK-Cu has been studied at 1-10 nM in vitro [2], at 0.05-0.2% in topical formulations [1], and at approximately 3 mg/kg intraperitoneal in rodent fibrosis models [4]. TB-500 inherits dose conventions from full-length thymosin beta-4, including 6 mg/kg intraperitoneal in the 2010 rat stroke model [14] and 0.1% topical in the corneal Phase III [12]. The GLOW combination itself has no validated dose — commercial vials advertise 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 by vendor convention, not by literature-derived guidance [16]. The /dosage page covers research-context dosing in detail. ## What are the known risks or controversies around the components of GLOW? Three broad categories. First, none of the three components is FDA-approved for any human therapeutic indication, and BPC-157 was placed on the FDA Category 2 bulk drug substances list in September 2023, citing immune-reaction, manufacturing-impurity, and human-safety-data concerns [16]. Second, BPC-157's potent angiogenic effect has prompted theoretical concern about tumor neovascularization — no human data shows a causal link, but the mechanism makes the concern plausible [9, 18]. Third, vendor-supplied GLOW vials vary widely in component ratios, sterility testing, and third-party purity verification, and most published efficacy data is rodent intraperitoneal, which is a substantial inferential leap from human subcutaneous self-administration [16]. ## Is this site selling the GLOW blend or referring me to a provider? No. Telehealth GLOW is an independent editorial publisher. We summarize peer-reviewed research on GHK-Cu, BPC-157, TB-500, and the GLOW blend. We are not a clinic, we do not employ clinicians, we do not provide medical advice, and we do not manufacture, sell, distribute, or refer for any product. The 'telehealth' in our name is editorial framing — a position the publisher occupies relative to a fast-moving prescribing landscape, not a service we offer. See /about for the full editorial-entity statement. ## Why does the design split every heading into three offset color channels? The chromatic-aberration / RGB-split visual treatment is a deliberate editorial argument. GLOW is three separately-studied components presented as one blend, and the three colors literalize that decomposition — red for GHK-Cu (matrix), green for BPC-157 (angiogenesis), blue for TB-500 (migration). The three only fully superimpose in a few places on the site, just as the three peptides almost-but-do-not-quite combine into a single research record. Body text and small UI text stay clean off-white on near-black for AAA legibility — the chromatic split is strictly a display-heading treatment, gated behind prefers-reduced-motion for users who request it. --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription. --- # References — GLOW blend (GHK-Cu + BPC-157 + TB-500) research literature > Full citation list for the GLOW research-peptide blend literature summary. Eighteen primary references with DOIs and PubMed/PMC URLs covering GHK-Cu, BPC-157, and TB-500 / thymosin beta-4. The eighteen primary references behind this site, color-coded by component channel where the citation maps to a single peptide. ## Citation index The references below are numbered to match the inline [N] markers used across the site. Channel labels (R / G / B) indicate which GLOW component the citation primarily addresses; M denotes a methodological or biochemical source not tied to a single component. Where a peer-reviewed DOI is available it is included; otherwise the PubMed or PMC identifier is given. All linked sources are publisher pages or PubMed Central full-text records. Readers interested in the broader thymosin beta-4 program (parent of TB-500) or the full BPC-157 development history (including the unpublished PL-14736 Phase II) should follow the linked papers' own reference lists for the deeper trail. ## Citation notes by channel **Channel R / GHK-Cu** references [1, 2, 3, 4, 5, 17] cover the 1994 Mulder diabetic-ulcer trial (the most-cited controlled human result for GHK-Cu), the Pickart 2014 transcriptomic Connectivity Map paper, two mouse lung-injury and fibrosis studies, the hair-follicle ex vivo work, and a 2025 liposomal-formulation review. **Channel G / BPC-157** references [6, 7, 8, 9, 10, 16, 18] cover the tendon-fibroblast growth-hormone-receptor work, the Achilles tendon transection model, the Src-Caveolin-1-eNOS vasomotor pathway, the 2025 McGuire narrative review of human evidence, two Sikiric mechanistic syntheses, and the Pliva PL-14736 paper that anchors the unpublished Phase II trial. **Channel B / TB-500** references [11, 12, 13, 14, 15] cover the biochemical basis for thymosin beta-4 as the major intracellular G-actin sequestering peptide, the 2023 Phase III ophthalmic trial of RGN-259 in neurotrophic keratopathy, the 2004 Nature cardiac-regeneration paper, the 2010 rat embolic-stroke model, and the 2011 myoblast-chemoattractant study. The 2024 engineered tandem-Tβ4 work is also referenced where the corneal repair section discusses recent formulation progress. ## References [1] Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration. 1994;2(4):259-269. https://pubmed.ncbi.nlm.nih.gov/17147644/ [2] Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: Resetting the Human Genome to Health. BioMed Research International. 2014;2014:151479. https://onlinelibrary.wiley.com/doi/10.1155/2014/151479 [3] Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. https://pmc.ncbi.nlm.nih.gov/articles/PMC5295439/ [4] Zhang Q, Yan L, Lu J, Zhou X. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sciences. 2020;241:117117. https://pubmed.ncbi.nlm.nih.gov/31809714/ [5] Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839. https://pubmed.ncbi.nlm.nih.gov/17703737/ [6] Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/ [7] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. https://pubmed.ncbi.nlm.nih.gov/21030673/ [8] Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JHS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020;10:17078. https://www.nature.com/articles/s41598-020-74022-y [9] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(4). https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ [10] Sikiric P, Skrtic A, Gojkovic S, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals. 2023;16(5):676. https://www.mdpi.com/1424-8247/16/5/676 [11] Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clinical Ophthalmology. 2009;3:415-423. https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/ [12] Sosne G, Dunn SP, Kim C. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences. 2023;24(1):554. https://www.mdpi.com/1422-0067/24/1/554 [13] Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/ [14] Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682. https://pmc.ncbi.nlm.nih.gov/articles/PMC2907184/ [15] Tokura Y, Nakayama Y, Fukada SI, Nara N, Yamamoto H, Matsuda R, Hara T. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of Biochemistry. 2011;149(1):43-48. https://pubmed.ncbi.nlm.nih.gov/20880960/ [16] Sikiric P, Seiwerth S, Brcic L, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL 14736), is effective in the healing of colocutaneous fistulas in rats. Journal of Pharmacological Sciences. 2008;108(1):7-17. (Cited here as the anchor paper for the unpublished PL-14736 Phase II program and for the absence of any peer-reviewed full-GLOW combination study.) https://pubmed.ncbi.nlm.nih.gov/18818478/ [17] Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Pharmaceutics. 2025;17(1):52. https://pmc.ncbi.nlm.nih.gov/articles/PMC11721469/ [18] Sikiric P, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Pharmaceuticals. 2025;18(10):1450. https://www.mdpi.com/1424-8247/18/10/1450 [19] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/ --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription. --- # About — Telehealth GLOW editorial standards > Telehealth GLOW is an independent editorial publisher summarizing the peer-reviewed research on the GLOW research-peptide blend. We are not a clinic, not a telehealth provider, and do not sell any product. Who we are, what we publish, what we don't do — and why the word 'telehealth' is in our name. ## What this site is Telehealth GLOW is an independent editorial project that publishes summaries of the peer-reviewed research literature on the GLOW research-peptide blend — the three-component co-formulation of GHK-Cu, BPC-157, and TB-500 marketed under that community-derived name. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We do not provide telehealth services, prescriptions, or referrals to any provider. Our work is editorial commentary on publicly available science. The word 'telehealth' in our domain name is editorial framing — a position the publisher occupies relative to a fast-moving and heavily regulated prescribing landscape, not a claim about services this site offers. The most-searched intent around 'telehealth GLOW' is some version of 'can I get this prescribed virtually,' and the most-useful editorial response is a careful, sourced reading of the research and the regulatory posture that constrains the answer. That is what we publish. ## What we explicitly are not We are not a telehealth provider. We are not a clinic. We do not run a virtual prescribing service, an asynchronous-messaging consult model, or a video-visit platform. We do not have doctors on staff, pharmacists on staff, or a clinical team. We do not have a physical address that dispenses anything. We do not have a referral network of prescribers. If you arrived here looking for a telehealth visit, this is the wrong site — and the regulatory posture around the components of GLOW (see the FDA Category 2 status of BPC-157, in effect since September 2023) constrains that landscape regardless of where you look [16]. We are also not a vendor. We do not sell GHK-Cu, BPC-157, TB-500, the GLOW blend, or anything else. We are not affiliated with any vendor, compounding pharmacy, research-chemical distributor, or telehealth platform. The footer disclaimer on every page makes this explicit, and it is meant literally. ## Editorial methodology Every quantitative claim on this site cites a specific peer-reviewed paper. Dose values, study sizes, percentage effects, half-life numbers — all are traceable through the inline [N] markers to the references index. We work from PubMed, PubMed Central, ClinicalTrials.gov, journal publisher pages, and FDA-published documents. Where the literature is sparse or absent — as it is for the full GLOW combination — we say so plainly. We do not use anonymized expert opinion. We do not paraphrase Reddit or forum content. We do not invent representative case histories. If a claim is not in the indexed literature, we either do not write it or we mark its absence as the editorial point ('no peer-reviewed combination study exists'). We write in the third person, attribute every dose and effect to a specific study, and use the phrase 'studied at X in [species]' framing throughout. We do not recommend doses. We do not recommend administration routes. We do not endorse compounding pharmacies, vendors, or telehealth providers. ## Why the visual design looks the way it does The chromatic-aberration / RGB-split design language on this site is a deliberate editorial argument made through visual vocabulary. GLOW is three separately-studied compounds being marketed as one stack. The three pure-RGB primaries used as a structural legend — red for GHK-Cu, green for BPC-157, blue for TB-500 — literalize that decomposition on every page. Display headings carry a chromatic-split shadow that almost-but-does-not-quite register, just as the three peptides almost-but-do-not-quite combine into a single research record. Body text and small UI text remain clean off-white on near-black with AAA contrast at 17px — the chromatic-split treatment is strictly for display headings and decorative numerals, gated behind prefers-reduced-motion for users who request reduced motion. The aesthetic carries the argument; the reading layer stays calm. --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription. --- # Contact — Telehealth GLOW editorial corrections > Contact Telehealth GLOW for editorial corrections, citation suggestions, or research-literature questions. Not a clinical contact form. Not a prescribing service. Send us a citation we missed, a correction, or a research-literature question. We are not a clinical contact form and cannot answer prescribing or product questions. ## What we can answer Editorial corrections. Missing or mis-cited references. Suggestions for newly-indexed papers that should appear in a future revision of the /research or /references pages. Questions about the editorial methodology described on /about. Permission requests to quote or excerpt content (we generally grant these for non-commercial use with attribution; please ask before any commercial use). ## What we cannot answer Medical questions about whether GLOW or any of its components is appropriate for any individual. Prescribing questions. Compounding-pharmacy questions. Sourcing or vendor questions. Telehealth referrals. Dosing questions framed as personal advice. Product complaints or returns (we do not sell anything). We are an editorial publisher, not a clinician and not a vendor. Routine product, prescribing, and dosing questions should go to a licensed healthcare provider in your jurisdiction. The disclaimer at the bottom of every page on this site applies to every interaction with us as well. ## Reach the editor Use the form below for the categories above. Replies are best-effort and may take several days. We do not collect or store personal health information; please do not send any. Messages are treated as editorial correspondence — if your message contains a correction or citation, we may incorporate the substance of it (without identifying you) into a future site revision. *Form fields: Name (optional), Email (required for reply), Subject (required), Message (required, 5000 characters max). The form posts to a generic email endpoint. No backend account is created.* --- An independent editorial reading of three separately-studied research peptides — not a clinic, not a vendor, not a prescription.